Drug intelligence / Profile preview

AIOVA

Development stage: Preclinical
Lead developer: KWHC
Modality: Stem Cell Therapies → Cell Therapies

Overview

**AIOVA** is a preclinical, proprietary combinatory stem cell therapy being developed by KWHC for complex injuries. The program is described as using stem cell and perinatal-derived cellular components with the intended goal of promoting tissue repair and functional recovery; no defined molecular target, cell composition, manufacturing process, route of administration, or dosage form has been publicly disclosed.

Beyond the preview

Go deeper on AIOVA.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AIOVA.

Explore the full profile